Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
Tag Archive for: IDO01
Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.